Skip to main content
. 2017 Sep 12;8(49):85984–85996. doi: 10.18632/oncotarget.20841

Figure 6. miR-296-5p and BOK silencing protect breast cancer cells from paclitaxel-induced apoptosis.

Figure 6

(A, B) Western blot analysis on MDA-MB-231 (A) and MDA-MB-468 cells (B) treated with vehicle or indicated dose of paclitaxel (Pac) using antibody against caspase-3. (C, D) Western blot analysis on MDA-MB-231 and MDA-MB-468 cells transfected with miR-296-5p in the presence and absence of paclitaxel (pac) using antibody against caspase-3. (E, F) Western blot analysis on MDA-MB-231 and MDA-MB-468 cells transfected with mock or BOK-siRNA in the presence and absence of paclitaxel (pac) using antibody against caspase-3. (G, H) Western blot analysis on MDA-MB-231 and MDA-MB-468 cells transfected with mock or Mcl-1-siRNA in the presence and absence of paclitaxel (pac) using antibody against caspase-3. Gel pictures are representative of three independent experiments.